A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer.
Posted Date: May 15, 2019
- Investigator: Olugbenga Olowokure
- Type of Study: Drug
This study will evaluate the good and bad effects of an oral drug called celecoxib when given in combination with FOLFOX chemotherapy. Celecoxib is approved by the FDA to treat arthritis and to prevent colon polyps in families with a genetic risk for colon cancer. The addition of celecoxib to FOLF
Criteria:
Eligible Patients Must Have Cancer Of The Colon, Which Has Been Surgically Removed, But Has Spread T
Keywords:
Calgb 80702, Colon Cancer, Gastroinestinal Canc, Gi Cancer, Resected
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu